People · Operator
Named in public records as an officer, director or promoter · active 2012–2014 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sorbent Therapeutics Inc | — | Pharmaceuticals | Series B | $58.6M | $221.0M | 2012 |
Marcus Goebel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marcus Goebel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Collier | 1 | 8 |
| James Healy | 1 | 8 |
| James I. Healy | 1 | 7 |
| Scott Minick | 1 | 7 |
| Markus Goebel | 1 | 4 |
| Linda Ara | 1 | 3 |
| Howard C. Dittrich | 1 | 2 |
| Randall Woods | 1 | 2 |
| Donald Joseph | 1 | 2 |
| Linda De Young | 1 | 1 |
| Detlef Albrecht | 1 | 1 |
| Jason P. Levin | 1 | 1 |
| Thomas P. O'Neil | 1 | 1 |
| Linda C. De Young | 1 | 1 |
| David I. Collier | 1 | 1 |
| William I. Rajski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.